
María Victoria
Mateos Manteca
Profesora Titular de Universidad
Publications (547) María Victoria Mateos Manteca publications
2025
-
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?
Journal of Clinical Oncology
-
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
The Lancet Oncology
-
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
Blood Advances, Vol. 9, Núm. 3, pp. 571-582
-
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy
American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102
-
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
-
Correction to: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development (Blood Cancer Journal, (2025), 15, 1, (15), 10.1038/s41408-025-01212-0)
Blood Cancer Journal
-
Daratumumab: a game changer in early myeloma
Blood
-
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
Annals of Oncology, Vol. 36, Núm. 4, pp. 361-374
-
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies
Annals of Hematology
-
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial
Clinical Lymphoma, Myeloma and Leukemia
-
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials
Clinical Lymphoma, Myeloma and Leukemia
-
Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma
Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132
-
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
The Lancet Haematology, Vol. 12, Núm. 4, pp. e269-e281
-
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 392, Núm. 2, pp. 138-149
-
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Blood cancer journal, Vol. 15, Núm. 1, pp. 15
2024
-
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
HemaSphere
-
A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma
Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica, Vol. 109, Núm. 3, pp. 867-876
-
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
European Journal of Haematology, Vol. 113, Núm. 5, pp. 593-605
-
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine, Vol. 391, Núm. 5, pp. 393-407